Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista da Sociedade Brasileira de Medicina Tropical |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822020000100346 |
Resumo: | Abstract INTRODUCTION: In the genesis of coronavirus disease (COVID-19), there is a process of endotheliitis associated with thrombotic changes, no studies have reported the use of acetylsalicylic acid (ASA) as a possible therapeutic approach. Statins could potentiate the ASA therapy. METHODS: This is a series of 14 cases with a laboratory-confirmed diagnosis of COVID-19. All patients underwent the ASA therapy. Those who had risk factors for vascular disease also underwent the high-potency statin therapy. When symptoms were totally or practically resolved, patients were discharged and advised to continue medications for a complementary time, according to the clinical evolution of each patient. RESULTS: The mean age of monitored patients was 48.6 years. A total of 78.6% patients presented with at least one comorbidity, which could have contributed as a risk factor for a poor prognosis in the evolution of COVID-19. Four patients had secondary bacterial infections; three patients needed hospitalization. None of the cases progress to stage III, and all patients had remission of symptoms, with 100% survival. CONCLUSIONS: the process of endothelial dysfunction in COVID-19 involves disseminated thrombosis, initially microvascular and later expansion into larger vessels. ASA could act as a secondary prophylaxis and prevent thrombosis from developing and reaching stage III of the disease. As this was a case series, we cannot provide definitive conclusions; however, this study allows us to formulate hypotheses and support clinical trials to evaluate benefits of the ASA therapy in the treatment of COVID-19. |
id |
SBMT-1_f90cb7ae11901ff67bc4ec80f6e41877 |
---|---|
oai_identifier_str |
oai:scielo:S0037-86822020000100346 |
network_acronym_str |
SBMT-1 |
network_name_str |
Revista da Sociedade Brasileira de Medicina Tropical |
repository_id_str |
|
spelling |
Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus diseaseCOVID-19AspirinThrombosisEndotheliumHydroxymethylglutaryl-CoA Reductase InhibitorsAbstract INTRODUCTION: In the genesis of coronavirus disease (COVID-19), there is a process of endotheliitis associated with thrombotic changes, no studies have reported the use of acetylsalicylic acid (ASA) as a possible therapeutic approach. Statins could potentiate the ASA therapy. METHODS: This is a series of 14 cases with a laboratory-confirmed diagnosis of COVID-19. All patients underwent the ASA therapy. Those who had risk factors for vascular disease also underwent the high-potency statin therapy. When symptoms were totally or practically resolved, patients were discharged and advised to continue medications for a complementary time, according to the clinical evolution of each patient. RESULTS: The mean age of monitored patients was 48.6 years. A total of 78.6% patients presented with at least one comorbidity, which could have contributed as a risk factor for a poor prognosis in the evolution of COVID-19. Four patients had secondary bacterial infections; three patients needed hospitalization. None of the cases progress to stage III, and all patients had remission of symptoms, with 100% survival. CONCLUSIONS: the process of endothelial dysfunction in COVID-19 involves disseminated thrombosis, initially microvascular and later expansion into larger vessels. ASA could act as a secondary prophylaxis and prevent thrombosis from developing and reaching stage III of the disease. As this was a case series, we cannot provide definitive conclusions; however, this study allows us to formulate hypotheses and support clinical trials to evaluate benefits of the ASA therapy in the treatment of COVID-19.Sociedade Brasileira de Medicina Tropical - SBMT2020-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822020000100346Revista da Sociedade Brasileira de Medicina Tropical v.53 2020reponame:Revista da Sociedade Brasileira de Medicina Tropicalinstname:Sociedade Brasileira de Medicina Tropical (SBMT)instacron:SBMT10.1590/0037-8682-0472-2020info:eu-repo/semantics/openAccessFlorêncio,Francisco Kleyton ZacariasTenório,Maiza de OliveiraMacedo Júnior,Aluísio Roberto AndradeLima,Sandro Gonçalves deeng2020-09-18T00:00:00Zoai:scielo:S0037-86822020000100346Revistahttps://www.sbmt.org.br/portal/revista/ONGhttps://old.scielo.br/oai/scielo-oai.php||dalmo@rsbmt.uftm.edu.br|| rsbmt@rsbmt.uftm.edu.br1678-98490037-8682opendoar:2020-09-18T00:00Revista da Sociedade Brasileira de Medicina Tropical - Sociedade Brasileira de Medicina Tropical (SBMT)false |
dc.title.none.fl_str_mv |
Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease |
title |
Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease |
spellingShingle |
Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease Florêncio,Francisco Kleyton Zacarias COVID-19 Aspirin Thrombosis Endothelium Hydroxymethylglutaryl-CoA Reductase Inhibitors |
title_short |
Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease |
title_full |
Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease |
title_fullStr |
Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease |
title_full_unstemmed |
Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease |
title_sort |
Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease |
author |
Florêncio,Francisco Kleyton Zacarias |
author_facet |
Florêncio,Francisco Kleyton Zacarias Tenório,Maiza de Oliveira Macedo Júnior,Aluísio Roberto Andrade Lima,Sandro Gonçalves de |
author_role |
author |
author2 |
Tenório,Maiza de Oliveira Macedo Júnior,Aluísio Roberto Andrade Lima,Sandro Gonçalves de |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Florêncio,Francisco Kleyton Zacarias Tenório,Maiza de Oliveira Macedo Júnior,Aluísio Roberto Andrade Lima,Sandro Gonçalves de |
dc.subject.por.fl_str_mv |
COVID-19 Aspirin Thrombosis Endothelium Hydroxymethylglutaryl-CoA Reductase Inhibitors |
topic |
COVID-19 Aspirin Thrombosis Endothelium Hydroxymethylglutaryl-CoA Reductase Inhibitors |
description |
Abstract INTRODUCTION: In the genesis of coronavirus disease (COVID-19), there is a process of endotheliitis associated with thrombotic changes, no studies have reported the use of acetylsalicylic acid (ASA) as a possible therapeutic approach. Statins could potentiate the ASA therapy. METHODS: This is a series of 14 cases with a laboratory-confirmed diagnosis of COVID-19. All patients underwent the ASA therapy. Those who had risk factors for vascular disease also underwent the high-potency statin therapy. When symptoms were totally or practically resolved, patients were discharged and advised to continue medications for a complementary time, according to the clinical evolution of each patient. RESULTS: The mean age of monitored patients was 48.6 years. A total of 78.6% patients presented with at least one comorbidity, which could have contributed as a risk factor for a poor prognosis in the evolution of COVID-19. Four patients had secondary bacterial infections; three patients needed hospitalization. None of the cases progress to stage III, and all patients had remission of symptoms, with 100% survival. CONCLUSIONS: the process of endothelial dysfunction in COVID-19 involves disseminated thrombosis, initially microvascular and later expansion into larger vessels. ASA could act as a secondary prophylaxis and prevent thrombosis from developing and reaching stage III of the disease. As this was a case series, we cannot provide definitive conclusions; however, this study allows us to formulate hypotheses and support clinical trials to evaluate benefits of the ASA therapy in the treatment of COVID-19. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822020000100346 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822020000100346 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/0037-8682-0472-2020 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Medicina Tropical - SBMT |
publisher.none.fl_str_mv |
Sociedade Brasileira de Medicina Tropical - SBMT |
dc.source.none.fl_str_mv |
Revista da Sociedade Brasileira de Medicina Tropical v.53 2020 reponame:Revista da Sociedade Brasileira de Medicina Tropical instname:Sociedade Brasileira de Medicina Tropical (SBMT) instacron:SBMT |
instname_str |
Sociedade Brasileira de Medicina Tropical (SBMT) |
instacron_str |
SBMT |
institution |
SBMT |
reponame_str |
Revista da Sociedade Brasileira de Medicina Tropical |
collection |
Revista da Sociedade Brasileira de Medicina Tropical |
repository.name.fl_str_mv |
Revista da Sociedade Brasileira de Medicina Tropical - Sociedade Brasileira de Medicina Tropical (SBMT) |
repository.mail.fl_str_mv |
||dalmo@rsbmt.uftm.edu.br|| rsbmt@rsbmt.uftm.edu.br |
_version_ |
1752122162117869568 |